본문 바로가기
KERD
논문KCI 등재

Effect of Gongjindan, a Traditional Korean Polyherbal Formula, on the Pharmacokinetics Profiles of Donepezil in Male SDRats (2) ― Single Oral Combination Treatment of Donepezil 10mg/kg with Gongjindan 100mg/kg, 1.5hr-intervals with 7-day Repeated Treatment ―

이영준|박수진|구세광|정대규|권오대
대한예방한의학회 (Society of Preventive Korean Medicine)|2013.08|대한예방한의학회지 (Society of Preventive Korean Medicine)|제17권 제2호|pp. 139-155

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

PharmacokineticsDrug-drug interactionsRatRepeat oral doseGongjindanDonepezil
주제분류한의학

초록

Purpose : This study was aim to evaluate effects of pharmacodynamics and toxicity in combination therapy of donepezil with Gongjindan. The effects of Gongjindan co-administration on the pharmacokinetics (PK) of donepezil were observed after single and 7-day repeated oral co-administration with 1.5hr-intervals, to evaluate synergic pharmacodynamics and reduce toxicity of combination therapy of donepezil with Gongjindan. Materials and Methods : After 10mg/kg of donepezil treatment, Gongjindan100mg/kg was administered with 1.5hr-intervals. The plasma were collected at 30min before administration, 30min, 1, 2, 3, 4, 6, 8 and 24hrs after end of first and last 7th donepezil treatment, and plasma concentrations of donepezil were analyzed using LC-MS/MS methods. Results : Gongjindan markedly inhibited the absorption of donepezilregardless of sample time, from 30min to 8hrs after end of first 1.5hr-interval co-administration as compared with donepezil single treated rats. Especially the absorption of donepezil was significantly decreased at 2, 4, 6 and 8hrs after co-administration as compared with donepezilsingle treated rats. Accordingly, the Cmax (-26.236%), tex:\small\textstyle$AUC_{0-t}$(-26.02%) and tex:\small\textstyle$AUC_{0-inf}$(-25.90%) of donepezil in 1.5hr-interval co-administered rats were dramatically decreased as compared with donepezilsingle treated rats, respectively. However, no meaningful changes on the plasma donepezil concentrations and pharmacokinetic parameters were detected after end of last 7th 1.5hr-interval co-administration as compared with donerezil single treated rats, except for non-significant slight increases of Tmax(16.67%) detected in co-administered rats as compared with donepezil single treated rats. Conclusion : These findings are considered as direct evidences that Gongjindan also decreased oral bioavailability of donerezil as inhibited the absorptions, when they were co-administered with 1.5hr-intervals, but they may be adapted after 7 days continuous repeated l.5hr-interval co-administration.

Abstract

Purpose : This study was aim to evaluate effects of pharmacodynamics and toxicity in combination therapy of donepezil with Gongjindan. The effects of Gongjindan co-administration on the pharmacokinetics (PK) of donepezil were observed after single and 7-day repeated oral co-administration with 1.5hr-intervals, to evaluate synergic pharmacodynamics and reduce toxicity of combination therapy of donepezil with Gongjindan. Materials and Methods : After 10mg/kg of donepezil treatment, Gongjindan100mg/kg was administered with 1.5hr-intervals. The plasma were collected at 30min before administration, 30min, 1, 2, 3, 4, 6, 8 and 24hrs after end of first and last 7th donepezil treatment, and plasma concentrations of donepezil were analyzed using LC-MS/MS methods. Results : Gongjindan markedly inhibited the absorption of donepezilregardless of sample time, from 30min to 8hrs after end of first 1.5hr-interval co-administration as compared with donepezil single treated rats. Especially the absorption of donepezil was significantly decreased at 2, 4, 6 and 8hrs after co-administration as compared with donepezilsingle treated rats. Accordingly, the Cmax (-26.236%), tex:\small\textstyle$AUC_{0-t}$(-26.02%) and tex:\small\textstyle$AUC_{0-inf}$(-25.90%) of donepezil in 1.5hr-interval co-administered rats were dramatically decreased as compared with donepezilsingle treated rats, respectively. However, no meaningful changes on the plasma donepezil concentrations and pharmacokinetic parameters were detected after end of last 7th 1.5hr-interval co-administration as compared with donerezil single treated rats, except for non-significant slight increases of Tmax(16.67%) detected in co-administered rats as compared with donepezil single treated rats. Conclusion : These findings are considered as direct evidences that Gongjindan also decreased oral bioavailability of donerezil as inhibited the absorptions, when they were co-administered with 1.5hr-intervals, but they may be adapted after 7 days continuous repeated l.5hr-interval co-administration.

참고문헌 (39)

  1. Birks J, "Donepezil for dementia due to Alzheimer’s disease", Cochrane data- base of systematic reviews (Online), (1) (2006)
  2. Rogers SL, "Perspectives in the management of Alzheimer’s disease: clinical profile of donepezil", Dementia and geriatric cognitive disorders, 9(Suppl 3), pp.29~42 (1998)
  3. Roman GC, "Donepezil: a clinical review of current and emerging indications. Expert opinion on pharmacotherapy", Expert opinion on pharmacotherapy, 5(1), pp.161~180 (2004)
  4. Rojas-Fernandez CH, "Successful use of donepezil for the treatment of dementia with Lewy bodies", The Annals of pharmaco- therapy, 35(2), pp.202~205 (2001)
  5. Malouf R, "Donepezil for vascular cognitive impairment", Cochrane database of systematic reviews (Online), (1) (2004)
  6. Moraes W, "Donepezil imp- roves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study", Chest, 133(3), pp.677~683 (2008)
  7. Riedel G, "Scopolamine-induced deficits in social memory in mice : reversal by donepezil", Behavioural brain research, 204(1), pp.217~225 (2009)
  8. Handen BL, "Safety and efficacy of donepezil in children and ado-lescents with autism : neuropsychological measures", Journal of child and adolescent psychopharmacology, 21(1), pp.43~50 (2011)
  9. PfizerCanada Inc., "PRODUCT MONOGRAPH PrARICEPT®(donepezilhydrochloride) Tablets 5 and 10 mg PrARICEPT RDTTM (donepezil hydrochloride) Rapidly Disinte- grating Tablets 5 and 10 mg Cholinesterase Inhibitor", FDA Submission Control No: 107207. 2007, ~ (2007)
  10. Dunn NR, "Adverse effects associated with the use of donepezil in general practice in England", Journal of psychopharmacology, 14(4), pp.406~408 (2000)
  11. Benazzi F, "Mania associated with donepezil", Journal of psychiatry & neuroscience, 24(5), pp.468~469 (1999)
  12. Umegaki H, "Discontinuation of donepezil for the treatment of Alzheimer’s disease in geriatric practice", International psychogeriatrics, 20(4), pp.800~806 (2008)
  13. Lockhart IA, "Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alz- heimer’s disease: systematic review of the ‘real-world’ evidence", Dementia and geriatric cognitive disorders, 28(5), pp.389~403 (2009)
  14. Tiseo PJ, "Con- current administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses", British journal of clinical pharmacology, 46(Suppl 1), pp.25~29 (1998)
  15. Tiseo PJ, "Concurrent administration of donepezil HCl and ketoconazole: assessment of pharma- cokinetic changes following single and multiple doses", British journal of clinical pharmacology, 46(Suppl 1), pp.30~34 (1998)
  16. Yasui-Furukori N, "The effects of Ginkgo biloba extracts on the pharmaco kinetics and pharmacodynamics of donepezil", Journal of clinical pharmacology, 44(5), pp.538~542 (2004)
  17. Tiseo PJ, "Concurrent administration of donepezil HCl and digoxin: assessment of pharmaco- kinetic changes", British journal of clinical pharmacology, 46(Suppl 1), pp.40~44 (1998)
  18. Tiseo PJ, "Con- current administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose adminis- tration in healthy volunteers", British journal of clinical pharmacology, 46(Suppl 1), pp.35~39 (1998)
  19. Tiseo PJ, "The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin", British journal of clinical pharmacology, 46(Suppl 1), pp.45~50 (1998)
  20. Kim YH, "The effect of Kong Jin Dan on the lipid metabolism in rats fed high fat-diet", J East-West Med, 14, pp.61~78 (2001)
  21. Kim YS, "The Effect of Gongjindan Aqua-acupuncture on the CD4+ T cell count at al. in rats were admini- stered with MTX", J Korean Acup Moxi Soc, 16, pp.179~202 (1999)
  22. 박치상, "拱辰丹의 성분 분석 및 抗酸化 작용에 미치는 영향", 대한본초학회지, 22(2), pp.51~63 (2007), 대한본초학회
  23. 성기문, "공진단이 MCAO모델 흰쥐에서 gliosis 억제에 미치는 영향", 대한한방내과학회지, 30(4), pp.674~684 (2009), 대한한방내과학회
  24. 황선미, "공진단이 CT105로 유도된 Alzheimer's disease 병태모델에 미치는 영향", 동의신경정신과학회지, 15(2), pp.103~118 (2004), 대한한방신경정신과학회
  25. 정효창, "공진단이 알츠하이머형 치매 환자에게 미치는 영향", 동의신경정신과학회지, 15(2), pp.141~148 (2004), 대한한방신경정신과학회
  26. 구세광, "Single Oral Dose Toxicity Test of Kong-Jin-Dan, a Polyherbal Formula in ICR Mice", 응용약물학회지, 15(4), pp.245~251 (2007), 한국응용약물학회
  27. Sang-Nam Lee, "Micronucleus Test of Kong-Jin-Dan, a Polyherbal Formula, in Bone Marrow Cells of Male ICR Mice", 한국독성학회지, 24(3), pp.213~218 (2008), 한국독성학회
  28. 정대규, "Effect of Gongjindon a Traditional Korean Polyherbal Formula, on the Pharmacokinetics Profiles of Donepezil in Male SDRats (1) -Single Oral Combination Treatment of Donepezil 10mg", kg with Gongjindan 100mg, 대한예방한의학회지, pp.2013, 17(1)[DOI]
  29. Gibaldi M, "Pharmacokinetics" (1982), Marcel-Dekker
  30. Chiou WL, "Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve", Journal of pharmacokinetics and biopharmaceutics, 6(6), pp.539~546 (1978)
  31. Fox JG, "Laboratory animal medicine" (1984), Academic Press Inc
  32. Tajima Y, "Biological reference data book on experimental animals" (1989), Soft Science Inc
  33. UHC drug monograph: Donepezil, "Dickinson BD", UHC Services Corporation, 1~14 (1996)
  34. Mihara M, "Pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy male volunteers", International journal of clinical pharmacology, therapy, and toxi- cology, 31(5), pp.223~229 (1993)
  35. Tiseo PJ, "Phar- macokinetic and pharmacodynamic profile of donepezil HCl following evening admi- nistration", British journal of clinical phar- macology, 46(Suppl 1), pp.13~18 (1998)
  36. Tiseo PJ, "Meta- bolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study", British journal of clinical pharmacology, 46(Suppl 1), pp.19~24 (1998)
  37. Rogers SL, "Long-term efficacy and safety of donepezil in the trea- tment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study", European neuro- psychopharmacology : the journal of the European College of Neuropsychopharmacology, 8(1), pp.67~75 (1998)
  38. Matsui K, "Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat", Drug metabolism and disposition: the biological fate of chemicals, 27(12), pp.1406~1414 (1999)
  39. Tiseo PJ, "An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function", British journal of clinical pharmacology, 46(Suppl 1), pp.51~55 (1998)

관련 논문AI추천

Effect of Gongjindon a Traditional Korean Polyherbal Formula, on the Pharmacokinetics Profiles of Donepezil in Male SDRats (1) -Single Oral Combination Treatment of Donepezil 10mg/kg with Gongjindan 100mg/kg within 5 min -구세광, 권오대, 박수진, 이영준, 정대규대한예방한의학회 · 대한예방한의학회지2013 · 제17권 제1호Effect of Gongjindan, a Polyherbal Formula on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (1) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan 100mg/kg within 5min -강수진, 구세광, 김승모, 박수진, 송창현, 이영준, 이창형, 한창현대한예방한의학회 · 대한예방한의학회지2014 · 제18권 제2호Effect of Gongjindan-gamibang on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (2) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan-gamibang 100 mg/kg, 3.5hr-intervals with 7-day Repeated Treatment -강수진, 구세광, 김승모, 박수진, 송창현, 이영준, 이창형, 한창현대한예방한의학회 · 대한예방한의학회지2015 · 제19권 제1호Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Single Oral Combination Treatment of Tamoxifen 50 mg/kg with GMODT 100 mg/kg with 2.5 hr-intervals -강수진, 구세광, 류은아, 송창현, 이봉효, 이영준, 최성훈, 한창현대한예방한의학회 · 대한예방한의학회지2017 · 제21권 제2호Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day Repeated Pretreated Rats with 8-day Repeated Co-administration곽민아, 구세광, 박성환, 박수진, 이영준대한예방한의학회 · 대한예방한의학회지2016 · 제20권 제2호생약제제의 약물동태 연구 및 상호작용강원구, 김은정, 노금한, 윤영란, 이혜원, 임미선, 정원필한국임상약학회 · 한국임상약학회지2010 · 제20권 제2호

이 간행물의 다른 논문 (12건)

한의학에서 환경의학의 중요성에 관한 고찰이해웅, 이상협, 김훈pp. 1-16『조선왕조실록』을 통해 본 한국의 차문화정지훈, 이상재pp. 17-28전국민을 대상으로 한 한의원과 한방병원 외래이용환자의 이용실태 및 특성비교연구 - 2011년 한방의료이용 및 한약소비실태조사 보고서(보건복지부)중 이용환자의 질병치료방법 및 치료효과를 중심으로 -조재국, 김현도, 이선동, 양준모, 최성용, 박해모pp. 29-46새로운 한의학 병인분류체계의 연구이기남, 이영준, 이선동, 임병묵, 박선주, 이해웅, 장보형, 이상재, 고성규, 신용철, 정명수, 황귀서, 박해모pp. 47-68의료생활협동조합 한의원의 일차의료서비스 수준 평가임병묵, 성태경pp. 69-78
원문 보기